Smart, sustainable manufacturing isn't just a future ambition – it's biopharma's next competitive advantage.
For years, sustainability in biopharma was treated as a compliance exercise: something important, but separate from business performance. That mindset is quickly becoming obsolete.
The industry is entering an era where the ability to manufacture sustainably will increasingly determine the ability to manufacture successfully.
As demand grows for advanced therapies, manufacturers face a difficult balancing act: delivering innovation faster, scaling production more efficiently, and reducing environmental impact at the same time. These are often presented as competing priorities. In reality, the organizations that will lead the next decade of biopharma are those that recognize they are inseparable.
Sustainability is no longer a constraint on growth. It is becoming a catalyst for innovation, resilience, and operational excellence.
Healthcare contributes nearly 5% of global greenhouse gas emissions, with biopharma playing a significant role. At the same time, regulatory expectations are increasing, investors are scrutinising environmental performance more closely, and customers are demanding greater transparency across the value chain. The question is no longer whether manufacturers should act, but how quickly they will adapt.
The future of biopharma won't be built by choosing between innovation and sustainability. It will be built by designing systems that deliver both. Implementation is becoming the new currency to invest in success.
What will define the manufacturing leaders of the next decade?
Manufacturing principles have been designed around a linear model for decades: take, make, dispose. That model is becoming increasingly difficult to justify in a resource-constrained world. The most forward-thinking organizations are rethinking waste not as an unavoidable outcome, but as evidence of untapped value. The shift towards circularity is not simply about reducing environmental impact; it's about extracting more value from every material, every process, and every investment.
Thinking of the end of life for materials is important, but what if that step could just be skipped? Sourcing sustainable instead of single-use materials saves the time and waste at the end of life of these materials, as there is a plan to use them before they even become waste. This is the goal for all products and materials, and the future of waste reduction through circularity.
Water scarcity is a global challenge and will only get increasingly harder to ignore. Without further measures, the supply of water will crumble and with it all processes that rely on it. Accelerating and advancing recycling and reuse technologies enables closed-loop systems that minimize consumption and protect local ecosystems. This is already reducing the risk that water scarcity poses to biopharma, and to people. Continuing to advance what is already in process will only make the future of the industry possible.
Transitioning from fossil fuels to clean energy sources such as solar arrays, wind turbines, biomethane, and hydropower – is becoming a reality. Integrating these sources of energy into current operations improves resilience, reduces risk from the volatility of energy costs, and creates more predictability with the cost of energy. A site's ability to produce its own energy guarantees significantly more control over potential future problems while relying on the grid's reliability. This all contributes to the dramatic reduction of Scope 1 and 2 emissions, providing tangible benefit to both the biopharma industry and the planet.
The next generation of therapies – mRNA vaccines, cell and gene treatments, personalized medicine – demand flexibility. Modular facilities allow rapid scaling or reconfiguration without major carbon costs. This agility ensures manufacturers can pivot quickly to meet emerging health needs while maintaining sustainability commitments.
Beyond the current scope
The efforts made now and, in the future, will be what drives progress forward. But this can only go so far, and progress will only grow at a linear rate without reimagining the status quo. Innovation and new approaches will be the drivers of positive change and future effective manufacturing.
As regulatory expectations evolve and organizations look to build more resilient operations, biodiversity is becoming increasingly recognized as a foundational business consideration. Yet it hardly appears in conversations surrounding sustainability. The Convention on Biological Diversity states that 80% of registered medicines come from plants or have been inspired by natural products. With rates like these, omitting considerations in manufacturing will be the equivalent to avoiding having a future to live in. The health of ecosystems influences everything from water quality and raw material availability to supply chain stability and site resilience. For an industry that depends on consistency, precision, and long-term security of supply, understanding and protecting nature is no longer optional, it's strategic.
The choice facing biopharma
The next decade will not be defined by who can build the biggest facilities, but by who can build the smartest ones.
Manufacturers that continue to view sustainability as a reporting exercise risk falling behind. Those that embed it into the design of their facilities, supply chains, and operating models will be better positioned to scale innovation, attract investment, and respond to changing market demands.
The industry has always excelled at solving some of humanity's greatest health challenges. The next challenge is ensuring those solutions can be delivered with a lighter environmental footprint. The opportunity is clear: smarter manufacturing can help us produce the therapies patients need while building a more resilient and sustainable future for the industry itself.